Anti-infective

For over 70 years, GSK has been tackling infectious diseases. Encompassing two-thirds of our pipeline, our extensive infectious disease portfolio includes vaccines, antibiotics, antivirals, and antifungals.

Doctor and patient

Urinary tract infections

60% of women in the United States have or will experience the discomfort of a urinary tract infection (UTI) at least once in their lifetime. Anywhere from 30% to 44% of women who experience a UTI will have a recurrence, often within three months.

Among the most common infectious diseases in the US, UTIs accounted for about 5.5 million outpatient and emergency department visits in 2018.  Further, UTIs place an economic burden on the US healthcare system, with direct and indirect costs estimated at around $3.5 billion per year.

GSK recognizes the importance of advanced research with the goal of ultimately improving patient outcomes.